November 03, 2025

Get In Touch

Proton Beam Therapy-Induced ADR Can Be Treated Effectively By Topical Corticosteroids: Study

Taiwan: A new study found that in patients with nasopharyngeal carcinoma (NPC), acute radiation dermatitis (ARD) induced by proton beam therapy (PBT) can be treated effectively by topical corticosteroid, silver sulfadiazine, and non-adhering silicone dressing. The article was published in the International Wound Journal.
Nasopharyngeal cancer (NPC) is a rare and geographically unique, squamous epithelial carcinoma occurring in the mucosal wall of the nasopharynx. Radiotherapy (RT) with or without the combination of chemotherapy is the major treatment for NPC. Proton beam therapy (PBT) is an advanced form of radiotherapy, with radiation treatment delivered by accelerated proton beams rather than X-rays. In recent years, PBT has been embraced for treating patients with NPC. However, Some studies have reported a high incidence of severe ARD for cancer patients treated with PBT.

Ko-Chun Fang, Kaohsiung Chang-Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan and colleagues initiated an observational study to investigate the prognostic factors and treatment outcomes of ARD among patients with NPC treated with PBT.
Researchers enrolled 57 patients with newly diagnosed NPC and were treated with PBT for the study. ARD was recorded weekly based on the criteria of Common Terminology Criteria for Adverse Events version 4.0 at treatment visits (1st to 7th weeks) and 1 week (8th week) and 1 month (11th week) after the completion of PBT. Topical corticosteroid was used when grade 1 ARD appeared, and silver sulfadiazine was added if ARD progressed to grade 2 or more. Non-adhering silicone dressing was applied over the cream, but only in the area with severe ARD.
Key findings of the study,
• The maximum ARD grade was 1, 2, and 3 in 45.6%, 42.1% and 12.3% of the patients, respectively.
• The peak incidence of grade 2 and 3 ARD was observed during the period of the 6th to 8th weeks.
• In 42.1% of the patients, ARD was treated with topical corticosteroid alone, 57.9% of the patients applied topical corticosteroid plus silver sulfadiazine and 43.8% of patients required non-adhering silicone dressing to cover severe skin wound area.
• In the 11th week, most grade 2 and 3 ARD had disappeared and 93.0% of the patients had ARD of grade 1 or lower.
• In the binary logistic regression model, habitual smoking and N2 to N3 nodal status were identified as independent predictors of grade 2 and 3 ARD.
Based on their observation, the authors conclude that ARD is a major concern for patients with NPC treated with PBT, especially those with a smoking habit or advanced nodal status and topical corticosteroids, silver sulfadiazine, and non-adhering silicone dressing are effective for treating these PBT-induced ARD induced.
Reference:
Ko-Chun Fang,Chih-Hung Lee,Hui-Ching Chuang,Tai-Lin Huang,Chih-Yen Chien,Wen-Ling Tsai,Fu-Min Fang. First published: 26 July 2022 https://doi.org/10.1111/iwj.13897

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!